奥沙利铂联合卡培他滨治疗晚期大肠癌的临床评价被引量：1

下载PDF

导出

摘要目的:观察奥沙利铂联合卡培他滨治疗晚期大肠癌的疗效和毒副反应。方法:选择42例术后有残留病灶或复发转移有可测量病灶的晚期大肠癌患者,静脉滴注奥沙利铂130mg/m2,第1天;卡培他滨2500mg/m2,分早晚2次口服,第1～14天,每3周为1周期。结果:42例患者中,CR3例,PR18例,SD11例,PD10例,近期有效率(CR+PR)为50.0%,中位生存期(MST)13个月,中位疾病进展时间(TTP)7.9个月。毒副反应主要为手足综合征、神经毒性,多为Ⅰ～Ⅱ度。结论:奥沙利铂联合卡培他滨的方案疗效好,毒副反应较小,患者易耐受,生活质量得到提高。

作者于炳旗王晓春张刚李中

机构地区河北大学附属医院肿瘤科

出处《亚太传统医药》 2007年第9期42-44,共3页 Asia-Pacific Traditional Medicine

关键词奥沙利铂卡培他滨大肠癌

分类号 R574.6 [医药卫生—消化系统]

引文网络
相关文献

参考文献10

1MiwaM;UraM;NishidaM.Designofanovaloralfluoropyrimidinecarbamate,capecitabine,whichgenerates5 fluoroura cilselectively intumors by enzymes concentrated inhumanliver and cancertissue[J],1998(08). 被引量：1
2潘启超;胥彬.肿瘤药理学与化学治疗学,2000. 被引量：1
3De Gramont A;Figer A;SeymourM.Leucovorin and flu-orouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer[J],2000(16). 被引量：1
4Borner MM;Dietrich D;StuppR.Phase Ⅱ study of capecitabine and oxaliplatin I n first and secong line treatment of advanced or metastatic colorectal cancer[J],2002(07). 被引量：1
5林万隆,陈强.奥沙利铂的药理作用及临床应用[J].中国肿瘤临床,2000,27(11):872-874. 被引量：333
6BakerDE.Oxaliplatin:a new way drug for the treatment of meta static carcinoma of the colonorrectum,2003(01). 被引量：1
7周际昌主编..实用肿瘤内科学[M].北京:人民卫生出版社,2003:818.
8王宝成,毕经旺,李志.靶向化疗——氟化嘧啶类药物的研究进展[J].国外医学（肿瘤学分册）,2001,28(6):447-451. 被引量：73
9蔡三军蔡国响.卡培他滨在结直肠癌中的应用.中华胃肠外科杂志,2002,5(3):295-295. 被引量：19
10HoffPM;AnsariR;BatistG.Comparision of oralcapecitabine versus intravenous fluor ouracil Pluslencovorin as first line treatment in 605 patients with metastatic colorectalcancer.Results ofa randomized phase Ⅲ study,2001(08). 被引量：1

二级参考文献18

1Li X M，Arch Toxicol，1998年，72卷，9期，574页被引量：1
2Koizumi W, Saigenji K, Nakamaru N,et al. Prediction of response to 5'-deoxy-5-fluorouridine (5'-DFUR) in patients with inoperable advanced gastric cancer by immunostaining of thymidine phosphorylase/platelet-derived endothelial cell growth factor [J]. Oncology,1999;56(3) :215-222. 被引量：1
3Takiguchi N, Nakajima N, Saitoh N, et al. A phase Ⅲ randomized study comparing oral doxifluridine and oral 5-fluorouracil after curative resection of gastric cancer[J]. Int J Oncol, 2000 , 6 (5): 1021-1027. 被引量：1
4Miyadera K, Sumizawa T, Haraguchi M, et al . Role of thymidine phosphorylase activity in the angiogenic effect of platelet derived endothelial cell growth factor/thymidine phosphorylase[J]. Cancer Res,1995,55(8): 1687-1690. 被引量：1
5Maeda K, Chung YS, Ogawa Y, et al. Thymidine phosphorylase/platelet-derived endothelial cell growth factor expression associated with hepatic metastasis in gastric carcinoma[J]. Br J Cancer, 1996,73 (8): 884-888. 被引量：1
6Mata JF, Garcia Manteiga JM, Lostao MP, et al. Role of the human concentrative nucleoside transporter (hCNT1) in the cytotoxic action of 5 [Prime] - deoxy- 5- fluorouridine, an active intermediate metabolite of capecitabine, a novel oral anticancer drug[J ]. Mol Pharmacol,2001,59(6): 1542. 被引量：1
7Miwa M, UraM, NishidaM, etal. Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue[J]. Eur J Cancer, 1998,34(8) :1274-1281. 被引量：1
8Reigner B, Blesch K, Weidekamm E. Clinical pharmacokinetics of capecitabine[J]. Clin Pharmacokinet,2001,40(2) :85-104. 被引量：1
9Blum JL, Jones SE, Buxdar AU, et al. Multicenter phase Ⅱ study of capecitabine in paclitaxel-refractory metastatic breast cancer[J]. J Clin Oncol, 1999,17 ( 2): 485 -493. 被引量：1
10O'shaughnessy J, Moiseyenko V, Bell D, et al. A randomized phase Ⅱ study of Xeloda (capecitabine) vs CMF as first line chemotherapy of breast cancer in women aged≥55 years[J]. Proc Am Soc Clin Oncol, 1998,17:398-406. 被引量：1